This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Immunology, Other  • Prognosis/ Outcomes  • Neuroendocrinology  • Neurology, Other  • Otolaryngology/ Head & Neck Surgery  • Inflammatory Disease of Head & Neck  • Drug Therapy  • Alert me on articles by topic

Long-term Follow-up of 48 Treated Patients

Thomas F. Scott, MD; Kristin Yandora, DO; April Valeri, BA; Carol Chieffe, RN, MSCN; Carol Schramke, PhD

Arch Neurol. 2007;64(5):691-696.

Background  Neurosarcoidosis (NS) is a relatively rare neurologic disorder for which no accepted treatment guidelines are available. Treatment with corticosteroids has been described as the primary means of controlling progressive symptoms. However, some physicians have recently advocated early intervention with alternative immunosuppressive therapies in patients who present with disabling symptoms.

Objective  To investigate our experience during the last decade regarding alternative immunosuppressive treatments, including corticosteroids and alternative therapies, in patients with NS.

Design  Observational, retrospective, consecutive case series with longitudinal follow-up.

Setting  Allegheny Neurological Clinic.

Patients  Seventy-eight patients with sarcoidosis were evaluated and classified as having possible, probable, or definite NS according to accepted criteria. Five cases of isolated NS were also included.

Main Outcome Measures  Patients with probable, definite, or isolated NS were scored before treatments and at final follow-up using estimated modified Rankin scores and the Disease Steps in Multiple Sclerosis scales.

Results  Forty-three patients were categorized as having either definite or probable NS according to accepted criteria and an additional 5 as having isolated NS. Thirty patients were categorized as having possible NS and were not included in the analysis of treatment response. Patients had a mean ± SD number of visits of 7.2 ± 6.4 and were followed up for a mean ± SD of 44.1 ± 43.6 months. Twenty patients were treated with pulse and/or maintenance corticosteroids alone. Twenty-six patients were treated with alternative immunosuppressive medications, with 23 of them receiving these medications at the time of diagnosis or within 6 months of the diagnosis of NS. Of the patients treated with alternative immunosuppressive therapies, 18 (69%) improved, 4 (15%) remained stable, and 4 (15%) worsened (including 1 death). Of the patients treated with corticosteroids alone, 7 (35%) improved, 11 (55%) remained stable, and 2 (10%) worsened. Two patients received no treatment.

Conclusions  Approximately half of all patients with NS seen at our clinic were believed to have disabling disease and to be at high risk for disease progression. These high-risk patients were treated with corticosteroids plus alternative immunosuppressive therapy, and favorable outcomes were obtained in almost all patients. Toxic effects related to treatments were minimal.

Author Affiliations: Department of Neurology, Drexel University College of Medicine (Drs Scott and Schramke), Department of Neurology, Allegheny General Hospital (Dr Yandora and Mss Valeri and Chieffe), and Allegheny Neurological Associates (Mss Valeri and Chieffe), Pittsburgh, Pa.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sarcoidosis
Iannuzzi et al.
NEJM 2007;357:2153-2165.
FULL TEXT